Safety Study of MGD009 in B7-H3-expressing Tumors

• ClinicalTrials.gov Identifier: NCT02628535
• Recruitment Status: Terminated
• First Posted: December 11, 2015
• Last Update Posted: February 8, 2022
• Sponsor: MacroGenics
• Information provided by (Responsible Party): MacroGenics

Tracking Information

• First Submitted Date: November 20, 2015
• First Posted Date: December 11, 2015
• Last Update Posted Date: February 8, 2022
• Study Start Date: September 2015
• Actual Primary Completion Date: November 25, 2019 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 8, 2015)

Number of participants with adverse events [ Time Frame: 28 days after last dose of study drug ]

adverse events, serious adverse events

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: November 8, 2018)

• Peak plasma concentration [ Time Frame: 8 days ]
  PK of MGD009
• Number of participants that develop anti-drug antibodies [ Time Frame: first dose through 28 days after last dose of study drug ]
  Proportion of patients who develop anti-MGD0009 antibodies, immunogenicity
• Change in tumor volume [ Time Frame: Weeks 6, 15, 24, 33, 42, 51, 60, 69, 78, 87, 96, 105 ]
  Anti-tumor activity of MGD009 using both conventional RECIST 1.1 and immune-related RECIST criteria.

Original Secondary Outcome Measures (submitted: December 8, 2015)

• Peak plasma concentration [ Time Frame: 8 days ]
  PK of MGD009
• Number of participants that develop anti-drug antibodies [ Time Frame: first dose through 28 days after last dose of study drug ]
  Proportion of patients who develop anti-MGD0009 antibodies, immunogenicity
• Change in tumor volume [ Time Frame: Weeks 6, 15, 24, 33, 42, 51, 60, 69, 78, 87, 96, 105 ]
  Anti-tumor activity of MGD006 using both conventional RECIST 1.1 and immune-related RECIST criteria.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety Study of MGD009 in B7-H3-expressing Tumors
• Official Title: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
• Brief Summary: The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.

Detailed Description

This study is a Phase 1 open-label, dose escalation, cohort expansion, and efficacy follow-up study of MGD009 administered intravenously (IV) on an every-other-week schedule for up to one year (14 cycles).

The dose escalation phase is designed to characterize the safety and tolerability of MGD009 and to define the maximum tolerated or maximum administered dose (MTD/MAD). This phase will enroll patients with mesothelioma, bladder cancer, melanoma, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), ovarian cancer, thyroid cancer, triple-negative breast cancer (TNBC), pancreatic cancer, colon cancer, soft tissue sarcoma, or prostate cancer.

In the cohort expansion phase, 6 cohorts of 16 patients each will be enrolled to further evaluate the safety and potential efficacy of MGD009 administered at the MTD/MAD dose in patients with mesothelioma, bladder cancer, melanoma, SCCHN, NSCLC, or other specific tumors that express high levels of B7-H3. Pre- and on-study biopsies are required for melanoma patients in the cohort expansion phase. Two additional cohorts (up to15 patients each) will evaluate the use of prophylaxis therapies to mitigate toxicity.

The survival follow-up phase consists of the 2-year period after the final dose of study drug.

All tumor evaluations will be carried out by both Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC).

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Mesothelioma
• Bladder Cancer
• Melanoma
• Squamous Cell Carcinoma of the Head and Neck
• Non Small Cell Lung Cancer
• Clear Cell Renal Cell Carcinoma
• Ovarian Cancer
• Thyroid Cancer
• Breast Cancer
• Pancreatic Cancer
• Prostate Cancer
• Colon Cancer
• Soft Tissue Sarcoma

Intervention

Biological: MGD009

B7-H3 x CD3 DART protein

Other Name: orlotamab

Study Arms

Experimental: MGD009

Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein

Intervention: Biological: MGD009

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: March 2, 2020): 67
• Original Estimated Enrollment (submitted: December 8, 2015): 114
• Actual Study Completion Date: November 25, 2019
• Actual Primary Completion Date: November 25, 2019 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically and/or cytologically proven unresectable locally advanced or metastatic tumors that express B7-H3 on the membrane or vasculature. The requirement for previous systemic therapy may be waived if a person was intolerant of standard front-line therapy
• Dose escalation phase prior systemic treatment requirements:
• pleural mesothelioma, pancreatic cancer: 1-3 prior treatments
• urothelial, SCHNN, prostate, soft tissue sarcoma, prostate cancer, TNBC, ccRCC, NSCLC: 1-5 prior treatments
• ovarian cancer: 2-4 prior treatments
• colon cancer: 2-4 prior treatments
• cutaneous melanoma: at least 1 prior treatment (including immunotherapy).
• Patients with prior immune checkpoint inhibitors must have related toxicities reduced to Grade 0, 1, or baseline
• Measurable disease per RECIST 1.1 criteria
• Easter Cooperative Oncology Group (ECOG) performance status 0 or 1
• Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

• Patients with central nervous system (CNS) involvement must have been treated, be asymptomatic, do not exhibit progression of CNS metastases on MRI or CT within 28 days, and do not have concurrent leptomeningeal disease or cord compression.
• Clinically significant pulmonary compromise within 28 days of first dose, including pneumonia, pneumonitis, requirement for supplemental oxygen). use to maintain adequate oxygenation, or pleural effusion sufficient to warrant pleurocentesis or any history of ≥ Grade 3 drug induced or radiation pneumonitis.
• History of autoimmune disease with certain exceptions such as vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within the past 2 years, patients with history of Hashimoto's or Grave's disease that are now euthyroid clinically and by lab testing
• History of clinically-significant cardiovascular disease, or cardiac arrhythmias, including atrial fibrillation at screening or day of treatment
• History of clinically-significant gastrointestinal (GI) disease; GI perforation within 1 year; GI bleeding or acute pancreatitis within 3 months; or diverticulitis within 4 weeks of first study drug administration
• Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration
• Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction (PCR)
• Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
• History of allogeneic bone marrow, stem cell, or solid organ transplant
• Treatment with systemic cancer therapy or investigational therapy within 3 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration
• Trauma or major surgery within 4 weeks of first study drug administration
• Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Canada, United States

Administrative Information

• NCT Number: NCT02628535
• Other Study ID Numbers: CP-MGD009-01
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: MacroGenics
• Original Responsible Party: Same as current
• Current Study Sponsor: MacroGenics
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: MacroGenics
• Verification Date: February 2022